Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
Zenopa were extremely helpful in finding positions that suited my skill-set and experience. Zenopa has as friendly yet professional approach which helped them identify the role and level I was aspirin...
David, 2013

Almirall and Forest announce positive COPD trial results

7 January 2010 00:00 in Pharmaceutical Company Product News


Almirall and Forest Laboratories have announced that a phase III trial that compared the chronic obstructive pulmonary disease (COPD) therapy aclidinium bromide BID with a placebo has yielded positive results.

In a statement, the companies explained that the study met its primary endpoint of having aclidinium bromide producing statistically significant changes from baseline in the morning pre-dose trough FEV versus the placebo after three months.

Commenting on the news, Per-Olof Andersson, executive director of research and development at Almirall, said that the firm is "encouraged" by the fruitful top-line results.

The results are consistent with earlier research which compared aclidinium with tiotropium and a placebo.

Lawrence Olanoff, president and chief operating officer of Forest Laboratories, added: "These data suggest that aclidinium administered BID provides a clinically-important bronchodilatory effect with good tolerability in patients with COPD."

This news follows Alimirall's recent announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for its silodosin drug.

Other news stories from 07/01/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd